CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 500 filers reported holding CRISPR THERAPEUTICS AG in Q2 2021. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,558 | -24.1% | 34,331 | -6.1% | 0.02% | -11.8% |
| Q2 2023 | $2,053 | -14.1% | 36,563 | -30.8% | 0.02% | -15.0% |
| Q1 2023 | $2,389 | +131.0% | 52,820 | +107.6% | 0.02% | +33.3% |
| Q4 2022 | $1,034 | -99.9% | 25,441 | +47.7% | 0.02% | 0.0% |
| Q3 2022 | $1,125,000 | -4.3% | 17,220 | +10.9% | 0.02% | +25.0% |
| Q4 2021 | $1,176,000 | +13.6% | 15,522 | +67.9% | 0.01% | -14.3% |
| Q3 2021 | $1,035,000 | +238.2% | 9,246 | +267.8% | 0.01% | +250.0% |
| Q1 2021 | $306,000 | -65.8% | 2,514 | -57.0% | 0.00% | -55.6% |
| Q4 2020 | $894,000 | +237.4% | 5,842 | -6.4% | 0.01% | -40.0% |
| Q1 2020 | $265,000 | – | 6,242 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |